MENU
+Compare
CTMX
Stock ticker: NASDAQ
AS OF
Dec 12 closing price
Price
$4.19
Change
+$0.13 (+3.20%)
Capitalization
709.93M

CTMX CytomX Therapeutics Forecast, Technical & Fundamental Analysis

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment... Show more

Industry: #Biotechnology
CTMX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for CTMX with price predictions
Dec 11, 2025

Aroon Indicator for CTMX shows an upward move is likely

CTMX's Aroon Indicator triggered a bullish signal on November 17, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 118 similar instances where the Aroon Indicator showed a similar pattern. In of the 118 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CTMX advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CTMX moved out of overbought territory on November 07, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 49 cases where CTMX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on December 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CTMX as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CTMX turned negative on December 02, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTMX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CTMX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.609) is normal, around the industry mean (28.362). P/E Ratio (13.967) is within average values for comparable stocks, (51.986). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.836). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (4.354) is also within normal values, averaging (336.196).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CTMX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

CTMX is expected to report earnings to rise 2.67% to -9 cents per share on March 04

CytomX Therapeutics CTMX Stock Earnings Reports
Q4'25
Est.
$-0.09
Q3'25
Missed
by $0.04
Q2'25
Beat
by $0.06
Q1'25
Beat
by $0.21
Q4'24
Beat
by $0.43
The last earnings report on November 06 showed earnings per share of -9 cents, missing the estimate of -5 cents. With 1.72M shares outstanding, the current market capitalization sits at 709.93M.
A.I. Advisor
published General Information

General Information

an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
151 Oyster Point Boulevard
Phone
+1 650 515-3185
Employees
122
Web
https://www.cytomx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FOVAX26.740.26
+0.98%
First Trust/Confluence Small Cap Val A
TICHX30.930.23
+0.75%
Nuveen Large Cap Responsible Eq I
MKCPX28.610.06
+0.21%
BlackRock Balanced K
SWLSX43.65-0.05
-0.11%
Schwab Large-Cap Growth
GSIOX31.77-0.99
-3.02%
Goldman Sachs Small Cap Gr Insghts Instl

CTMX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CTMX has been loosely correlated with MLEC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CTMX jumps, then MLEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CTMX
1D Price
Change %
CTMX100%
+4.10%
MLEC - CTMX
42%
Loosely correlated
-6.67%
BGMS - CTMX
39%
Loosely correlated
+0.67%
BCAB - CTMX
37%
Loosely correlated
+1.23%
HOWL - CTMX
36%
Loosely correlated
+1.87%
VCYT - CTMX
36%
Loosely correlated
-2.56%
More